DK2328601T3 - Linaclotid-holdige formuleringer til oral indgivelse - Google Patents

Linaclotid-holdige formuleringer til oral indgivelse Download PDF

Info

Publication number
DK2328601T3
DK2328601T3 DK09789142.8T DK09789142T DK2328601T3 DK 2328601 T3 DK2328601 T3 DK 2328601T3 DK 09789142 T DK09789142 T DK 09789142T DK 2328601 T3 DK2328601 T3 DK 2328601T3
Authority
DK
Denmark
Prior art keywords
linaclotide
oral administration
containing formulations
formulations
oral
Prior art date
Application number
DK09789142.8T
Other languages
English (en)
Inventor
Angelika Fretzen
Steven Witowski
Alfredo Grossi
Hong Zhao
Mahendra Dedhiya
Yun Mo
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2328601(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2328601T3 publication Critical patent/DK2328601T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09789142.8T 2008-08-15 2009-08-14 Linaclotid-holdige formuleringer til oral indgivelse DK2328601T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8942208P 2008-08-15 2008-08-15
US27333209P 2009-08-03 2009-08-03
US23172509P 2009-08-06 2009-08-06
PCT/US2009/004675 WO2010019266A2 (en) 2008-08-15 2009-08-14 Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration

Publications (1)

Publication Number Publication Date
DK2328601T3 true DK2328601T3 (da) 2020-04-14

Family

ID=41666602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09789142.8T DK2328601T3 (da) 2008-08-15 2009-08-14 Linaclotid-holdige formuleringer til oral indgivelse

Country Status (32)

Country Link
US (7) US20120213846A1 (da)
EP (2) EP3701962A1 (da)
JP (10) JP5770629B2 (da)
KR (11) KR20220100101A (da)
CN (5) CN105168114A (da)
AU (1) AU2009282446B2 (da)
BR (1) BRPI0917807A2 (da)
CA (1) CA2732892C (da)
CL (1) CL2011000314A1 (da)
CO (1) CO6351746A2 (da)
CY (1) CY1122801T1 (da)
DK (1) DK2328601T3 (da)
EA (1) EA201170337A1 (da)
ES (1) ES2785980T3 (da)
GE (1) GEP20156209B (da)
HK (1) HK1219062A1 (da)
HR (1) HRP20200512T2 (da)
HU (1) HUE049023T2 (da)
IL (1) IL211028A (da)
LT (1) LT2328601T (da)
MX (4) MX385591B (da)
NZ (1) NZ591713A (da)
PE (2) PE20110543A1 (da)
PH (1) PH12015501579B1 (da)
PL (1) PL2328601T3 (da)
PT (1) PT2328601T (da)
RS (1) RS60101B1 (da)
SG (1) SG193801A1 (da)
SI (1) SI2328601T1 (da)
SM (1) SMT202000179T1 (da)
WO (1) WO2010019266A2 (da)
ZA (1) ZA201101523B (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
EP2373296B1 (en) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2011017502A2 (en) * 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
RU2012109415A (ru) * 2009-08-13 2013-09-20 Айронвуд Фармасьютикалз, Инк. Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
EP2521561B1 (en) * 2009-11-03 2017-07-26 Ironwood Pharmaceuticals, Inc. Linaclotide for the treatment of chronic constipation
US8507447B2 (en) 2009-11-09 2013-08-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
RU2012128509A (ru) 2009-12-07 2014-01-20 Айронвуд Фармасьютикалз, Инк. Способы лечения заболеваний желудочно-кишечного тракта
CN102869677B (zh) 2010-02-17 2015-07-08 硬木药品公司 胃肠病症的治疗
CA2808091C (en) 2010-08-11 2019-05-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
WO2012034068A1 (en) * 2010-09-11 2012-03-15 Ironwood Pharmaceuticals, Inc. Treatment of constipation-predominant irritable bowel syndrome
US9616097B2 (en) * 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012037380A2 (en) 2010-09-15 2012-03-22 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9527887B2 (en) 2011-06-08 2016-12-27 Ironwood Pharmaceutical, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
US20140242158A1 (en) * 2011-09-30 2014-08-28 Astellas Pharma, Inc. Granular Pharmaceutical Composition
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
WO2014118180A1 (en) * 2013-01-30 2014-08-07 Sandoz Ag Crystalline form of linaclotide
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
UA119335C2 (uk) 2013-12-11 2019-06-10 Айронвуд Фармасьютикалз, Інк. Композиції лінаклотиду з затриманим вивільненням
WO2016024291A1 (en) * 2014-08-11 2016-02-18 Sun Pharmaceutical Industries Ltd. Linaclotide stable composition
EP3006045B3 (en) * 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
CN104569245A (zh) * 2014-12-08 2015-04-29 江苏泰洁检测技术有限公司 一种工作场所脂肪族胺类中环己胺浓度测定方法
US20180008547A1 (en) * 2015-02-02 2018-01-11 Aurobindo Pharma Ltd Stable Compositions comprising Linaclotide
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide
CA2997343A1 (en) 2015-10-07 2017-04-13 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018119191A1 (en) 2016-12-21 2018-06-28 Ironwood Pharmaceuticals Inc. Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
CN107669700A (zh) * 2017-09-14 2018-02-09 湖南晓林生物科技发展有限公司 一种治疗溃疡性结肠炎的药物及其制备方法
BR112021000201A2 (pt) 2018-07-09 2021-08-10 Abbott Laboratories Gmbh composição farmacêutica contendo um peptídeo
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN112121021B (zh) * 2019-06-24 2022-03-25 深圳翰宇药业股份有限公司 一种含利那洛肽的药物组合物及其制备方法
JP2021104941A (ja) * 2019-12-26 2021-07-26 ニプロ株式会社 薬物高含有量錠剤及びその製造方法
WO2022002369A1 (en) * 2020-06-30 2022-01-06 Ocvirk Soeren Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof
CN113616616A (zh) * 2021-09-07 2021-11-09 四川国为制药有限公司 一种利那洛肽胶囊制剂及其制备方法
US20230106943A1 (en) * 2021-09-17 2023-04-06 Peptilogics, Inc. Engineered antimicrobial peptides and usage thereof
CN114632141B (zh) * 2022-04-19 2023-08-01 苏州中化药品工业有限公司 一种含利那洛肽的药物组合物、胶囊制剂及其制备方法
CN116672309A (zh) * 2023-07-26 2023-09-01 北京普诺旺康医药科技有限公司 干混悬药物组合物

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658973A5 (fr) 1983-12-29 1986-12-31 Nestle Sa Produit aromatisant.
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JPS649938A (en) 1987-06-30 1989-01-13 Agency Ind Science Techn Oral ingestive composition
EP0420964A4 (en) 1989-04-11 1991-09-25 Immunobiology Research Institute, Inc. Lyophilized peptide formulations
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5221495A (en) 1990-04-13 1993-06-22 Colgate-Palmolive Company Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
ZA965368B (en) * 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5916582A (en) 1996-07-03 1999-06-29 Alza Corporation Aqueous formulations of peptides
RO119862B1 (ro) 1996-07-03 2005-05-30 Alza Corporation Formulare stabilă neapoasă şi procedeu pentru prepararea acesteia
US20020151502A1 (en) * 1997-10-09 2002-10-17 Albert Sattin Tri-peptides for neurological and neurobehavior applications
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
US6087478A (en) * 1998-01-23 2000-07-11 The Rockefeller University Crystal of the N-terminal domain of a STAT protein and methods of use thereof
EP1098636A1 (en) 1998-07-23 2001-05-16 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
CN1315916A (zh) * 1998-09-04 2001-10-03 盖普拉斯特有限公司 容器
WO2000032172A1 (en) 1998-11-27 2000-06-08 Kanji Takada An oral formulation for gastrointestinal drug delivery
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US6699997B2 (en) 2000-06-28 2004-03-02 Teva Pharmaceutical Industries Ltd. Carvedilol
FR2811884B1 (fr) 2000-07-21 2003-01-31 Oreal Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2001296389A1 (en) 2000-09-29 2002-04-08 Cognetix, Inc. Stable peptide formulations
US6896906B2 (en) 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
AU2002235520A1 (en) 2001-02-02 2002-08-19 Pharmacia Corporation Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer
GB0104371D0 (en) 2001-02-22 2001-04-11 Clariant Int Ltd Color improving stabilizing compositions comprising leucine
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
DE60233040D1 (de) 2001-03-29 2009-09-03 Synergy Pharmaceuticals Inc Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
AU2002355542A1 (en) 2001-08-09 2003-02-24 Doctor's Signature Sales And Marketing International Corp. ((Dba)) Life Force International Protonic formulation
US20030104996A1 (en) 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
JP2005530682A (ja) * 2001-12-21 2005-10-13 ノボ　ノルディスク　アクティーゼルスカブ 修飾第ｖｉｉ因子ポリペプチドの液体組成物
JP2003201256A (ja) 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
DE10261126A1 (de) * 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
AU2003283688A1 (en) 2002-12-11 2004-06-30 Pfizer Products Inc. Controlled-release of an active substance into a high fat environment
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
KR101227626B1 (ko) * 2003-01-28 2013-02-01 아이언우드 파마슈티컬스, 인코포레이티드 위장병 치료 방법 및 위장병 치료용 조성물
DE602004012745T2 (de) 2003-05-14 2009-04-09 Indus Biotech Pvt. Ltd. Synergistische zusammensetzung zur behandlung von diabetes mellitus
NZ543859A (en) * 2003-06-10 2008-01-31 Lg Life Sciences Ltd Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers
US7494979B2 (en) 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
JP2007501866A (ja) 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
KR100560697B1 (ko) 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
WO2006071102A1 (en) 2004-12-30 2006-07-06 Dobeel Co., Ltd. Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same
US20090253634A1 (en) * 2005-08-19 2009-10-08 Microbia, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
WO2007044375A2 (en) 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
EP1991241A4 (en) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
WO2007101161A2 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ITMI20060629A1 (it) 2006-03-31 2007-10-01 Daniele Giovannone Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento
EP2046363A1 (en) 2006-07-10 2009-04-15 Österreichische Akademie der Wissenschaften Antimicrobial peptides
PT2359808E (pt) 2006-08-09 2013-08-28 Intarcia Therapeutics Inc Sistemas de entrega osmótica e montagens de pistão
KR101524880B1 (ko) 2006-08-31 2015-06-01 노파르티스 아게 Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
WO2008078189A2 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Factor vii and viia compositions
US8779090B2 (en) 2007-02-26 2014-07-15 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
MX385591B (es) 2008-08-15 2025-03-18 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral.
US20120039949A1 (en) * 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
EP2331077A2 (en) * 2008-09-04 2011-06-15 Ironwood Pharmaceuticals, Inc. Stable forlulation comprising therapeutic polypeptides for oral administration
EP2373296B1 (en) 2008-12-03 2016-08-03 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2011019819A1 (en) * 2009-08-12 2011-02-17 Forest Laboratories Holdings Limited Orally disintegrating compositions of linaclotide
US20130012454A1 (en) * 2009-07-06 2013-01-10 Ironwood Pharmaceuticals, Inc. Orally Disintegrating Compositions of Linaclotide
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration

Also Published As

Publication number Publication date
JP2022132383A (ja) 2022-09-08
JP2014139246A (ja) 2014-07-31
JP2016190870A (ja) 2016-11-10
KR20170016522A (ko) 2017-02-13
BRPI0917807A2 (pt) 2019-11-19
MX385591B (es) 2025-03-18
PL2328601T3 (pl) 2020-07-13
KR20120008017A (ko) 2012-01-25
HK1219062A1 (zh) 2017-03-24
IL211028A0 (en) 2011-04-28
PT2328601T (pt) 2020-04-30
US20100048489A1 (en) 2010-02-25
EP3701962A1 (en) 2020-09-02
MX373366B (es) 2020-05-26
MX2011001620A (es) 2011-03-25
WO2010019266A3 (en) 2010-06-03
PH12015501579A1 (en) 2016-02-22
ES2785980T3 (es) 2020-10-08
CN105168114A (zh) 2015-12-23
AU2009282446B2 (en) 2016-03-31
KR20180137043A (ko) 2018-12-26
KR20210145307A (ko) 2021-12-01
KR20200000462A (ko) 2020-01-02
KR20210043728A (ko) 2021-04-21
CA2732892A1 (en) 2010-02-18
PE20110543A1 (es) 2011-08-04
HUE049023T2 (hu) 2020-08-28
US20120213846A1 (en) 2012-08-23
RS60101B1 (sr) 2020-05-29
CN102186490B (zh) 2015-07-29
CY1122801T1 (el) 2021-05-05
KR20170138580A (ko) 2017-12-15
IL211028A (en) 2016-10-31
KR20200105730A (ko) 2020-09-08
SMT202000179T1 (it) 2020-05-08
EP2328601A2 (en) 2011-06-08
AU2009282446A1 (en) 2010-02-18
JP5770629B2 (ja) 2015-08-26
CL2011000314A1 (es) 2011-10-07
JP2019163340A (ja) 2019-09-26
CA2732892C (en) 2020-12-15
PE20151205A1 (es) 2015-08-31
GEP20156209B (en) 2015-01-12
LT2328601T (lt) 2020-04-27
US20220125734A1 (en) 2022-04-28
SI2328601T1 (sl) 2020-08-31
MX2020005326A (es) 2022-03-03
US20190029967A1 (en) 2019-01-31
CN102186490A (zh) 2011-09-14
CN117530912A (zh) 2024-02-09
KR20220100101A (ko) 2022-07-14
CN114668711A (zh) 2022-06-28
US20130273169A1 (en) 2013-10-17
CO6351746A2 (es) 2011-12-20
JP6473532B2 (ja) 2019-02-20
EP2328601B1 (en) 2020-01-22
JP2024015361A (ja) 2024-02-01
KR20230025926A (ko) 2023-02-23
HK1161978A1 (zh) 2012-08-17
EA201170337A1 (ru) 2012-01-30
JP2012500196A (ja) 2012-01-05
NZ591713A (en) 2013-07-26
JP6034327B2 (ja) 2016-11-30
MX390359B (es) 2025-03-20
KR20240025699A (ko) 2024-02-27
KR101704832B1 (ko) 2017-02-08
JP2021073297A (ja) 2021-05-13
HRP20200512T2 (hr) 2024-05-24
SG193801A1 (en) 2013-10-30
ZA201101523B (en) 2011-10-26
MX2019013628A (es) 2020-01-21
JP2018104469A (ja) 2018-07-05
HRP20200512T1 (hr) 2020-06-26
JP2025109853A (ja) 2025-07-25
US8802628B2 (en) 2014-08-12
PH12015501579B1 (en) 2022-02-11
WO2010019266A2 (en) 2010-02-18
CN109010254A (zh) 2018-12-18
US20210290554A1 (en) 2021-09-23
JP2018104468A (ja) 2018-07-05
US20230310329A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
DK2328601T3 (da) Linaclotid-holdige formuleringer til oral indgivelse
BRPI0820381A2 (pt) Formulações farmacêuticas
DK3061445T3 (da) Højkoncentrerede farmaceutiske formuleringer
DK2346495T4 (da) Farmaceutisk formulering 514
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
HUE046748T2 (hu) Orális beadásra szánt kortikoszteroid készítmények
DK3492069T3 (da) Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2419097A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2451274A4 (en) Pharmaceutical compositions
BRPI0814188A2 (pt) Formulações
BRPI0921654A2 (pt) formulação farmacêutica
EP2236149A4 (en) MEDICAL COMPOSITION
DK2285413T3 (da) Farmaceutisk sammensætning
EP2241304A4 (en) ORAL DENTAL COMPOSITION
BRPI0921313A2 (pt) composição farmaucêutica
BRPI1007484A2 (pt) composição farmacêutica para administração oral
BRPI0820198A2 (pt) composições farmacêuticas
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
IL213559A0 (en) Oral formulations
BRPI0912171A2 (pt) composição farmacêutica
BRPI0912656A2 (pt) formulação farmacêutica sólida
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan
BRPI0921301A2 (pt) composição farmacêutica
BRPI0919194A2 (pt) preparação sólida para administração oral